Scrum Ventures pumps ‘seven figures’ into Circulate Health to advance healthspan-focused plasma exchange services.
Therapeutic plasma exchange provider Circulate Health has secured a new strategic investment from Scrum Ventures to advance its clinical research and expand the commercial footprint of its services. The company develops precision TPE technologies aimed at improving human healthspan by removing circulating microplastics, environmental toxins, inflammatory proteins and other microscopic pollutants.
Circulate’s approach is rooted in long-standing medical uses of plasmapheresis for autoimmune, hematologic and neurological conditions, but applies the procedure to broader longevity and wellness goals. The company is already working with 28 longevity clinics across the United States, where clients reportedly pay up to $10,000 per session. It plans to expand its network beyond the US, with sites in Mexico, the Bahamas and Turkey slated to open soon.
“We’re entering a new era where more and more consumers are recognizing the benefits of TPE,” said Circulate CEO Brad Younggren. “Partnering with Scrum Ventures allows us to expand our research and continue the momentum we’ve seen since inception.”
The new undisclosed “seven-figure” investment follows a $12 million seed round closed earlier this year, led by Khosla Ventures. In Scrum Ventures, Circulate has landed a strategic partner whose portfolio spans human performance, wellness and emerging health technologies. Based in San Francisco and Tokyo, Scrum’s involvement reflects a growing link between sports-focused performance technologies and consumer-facing longevity services.
“The shift toward proactive, science-backed longevity care is one of the most important movements in modern health,” said Scrum partner Michael Proman. “Circulate is positioned at the center of that transformation—they’re building the first truly scalable, patient-centered platform in therapeutic plasma exchange.”
What is its therapeutic plasma exchange?
TPE involves drawing blood, separating plasma, discarding it and returning blood cells suspended in a replacement solution. In some protocols, intravenous immunoglobulin is added to further modulate immune activity. Circulate positions its platform as a way to potentially lower systemic inflammation and influence biological aging trajectories, building on evidence that persistent exposure to environmental particles and metabolic byproducts may contribute to age-related physiological decline.
Circulate’s scientific strategy is built on research conducted with the Buck Institute for Research on Aging. The company was co-founded by Younggren and Buck Institute CEO Eric Verdin, and its advisory network includes Buck investigator David Furman, who led a recently published single-blind clinical trial exploring the impact of TPE on molecular markers of aging.
The study, published in Aging Cell earlier this year, examined thousands of molecular signatures across the epigenome, proteome, metabolome, glycome and immune system, alongside functional measures such as balance and strength, in people receiving TPE treatment.
Participants receiving TPE showed reductions in biological age as assessed by multi-omics biomarkers. Investigators also observed shifts in immune cell composition associated with reversing age-related immune decline, including modulation of senescence-associated proteins. The data suggested that treatment effects were most substantial over the initial three sessions, with diminishing returns thereafter, indicating that spacing protocols or combining TPE with other interventions may optimize long-term outcomes.
Although the findings attracted significant attention because prior anti-aging research on plasma exchange had largely been limited to animal models or patients with chronic diseases, the study was small and short-term. It did not establish whether TPE can extend lifespan or improve long-term health in healthy adults, and larger controlled trials will be needed before the approach can be broadly adopted or justified at scale.
